Evidence map›Paper›PMID 36997247›Full record

ArticleBMJ open2023

Protocol for the CoNoR Study: A prospective multi-step study of the potential added benefit of two novel assessment tools in colorectal liver metastases technical resectability decision-making.

Kat L Parmar, Derek O'Reilly, Juan Valle, Michael Braun, Lee Malcomson, Robert P Jones, Fady Balaa, Myrddin Rees, Fenella K S Welsh, Rafik Filobbos and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04270851 (Colorectal Liver Metastases), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04270851 unknown statusnot on this map

Colorectal Liver Metastases: Novel Assessment Tools for Technical Resectability (The CoNoR Study)

TypeobservationalSponsorUniversity of ManchesterRan2020 to 2021Enrolled20ConditionsCancer, Cancer Metastatic, Colorectal Cancer, Liver Metastasis Colon CancerArmsLiMAx test, HepaT1ca magnetic resonance scan
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Kat L ParmarDivision of Cancer Sciences, The University of Manchester, Manchester, UK kat.parmar@manchester.ac.uk.ORCID 0000-0003-1414-6724
Derek O'ReillyDivision of Cancer Sciences, The University of Manchester, Manchester, UK.
Juan ValleDivision of Cancer Sciences, The University of Manchester, Manchester, UK.
Michael BraunDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Lee MalcomsonDivision of Cancer Sciences, The University of Manchester, Manchester, UK.
Robert P JonesDepartment of Hepatobiliary Surgery, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Fady BalaaDepartment of Surgery, Ottawa Hospital, Ottawa, Ontario, Canada.
Myrddin ReesDepartment of Surgery, Basingstoke and North Hampshire Hospital, Basingstoke, UK.
Fenella K S WelshDepartment of Surgery, Basingstoke and North Hampshire Hospital, Basingstoke, UK.
Rafik FilobbosDepartment of Radiology, Manchester University NHS Foundation Trust, Manchester, UK.
Andrew G RenehanDivision of Cancer Sciences, The University of Manchester, Manchester, UK.
University of Manchester · GBBasingstoke and North Hampshire Hospital · GBManchester University NHS Foundation Trust · GBThe Christie NHS Foundation Trust · GBUniversity of Liverpool · GBUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLiver resection is the only curative treatment for colorectal liver metastases (CLM). Resectability decision-making is therefore a key determinant of outcomes. Wide variation has been demonstrated in resectability decision-making, despite the existence of criteria. This paper summarises a study protocol to evaluate the potential added value of two novel assessment tools in assessing CLM technical resectability: the Hepatica preoperative MR scan (MR-based volumetry, Couinaud segmentation, liver tissue characteristics and operative planning tool) and the LiMAx test (hepatic functional capacity). METHODS AND ANALYSIS: This study uses a systematic multistep approach, whereby three preparatory workstreams aid the design of the final international case-based scenario survey:Workstream 1: systematic literature review of published resectability criteria.Workstream 2: international hepatopancreatobiliary (HPB) interviews.Workstream 3: international HPB questionnaire.Workstream 4: international HPB case-based scenario survey.The primary outcome measures are change in resectability decision-making and change in planned operative strategy, resulting from the novel test results. Secondary outcome measures are variability in CLM resectability decision-making and opinions on the role for novel tools. ETHICS AND DISSEMINATION: The study protocol has been approved by a National Health Service Research Ethics Committee and registered with the Health Research Authority. Dissemination will be via international and national conferences. Manuscripts will be published. REGISTRATION DETAILS: The CoNoR Study is registered with ClinicalTrials.gov (registration number NCT04270851). The systematic review is registered on the PROSPERO database (registration number CRD42019136748).

Indexed as

Colorectal NeoplasmsLiver NeoplasmsHumansProspective StudiesState MedicineSystematic Reviews as TopicGastrointestinal tumoursHepatobiliary surgery

Identifiers

PMID36997247
PMCPMC10069542
OpenAlexW4361271983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.